肝细胞癌TACE术后早期疗效预测价值的研究进展  

Research Progress on the Predictive Value of Early Curative Effect after TACE for Hepatocellular Carcinoma

作　　者：刘志祥 尹桂秀[1] 

机构地区：[1]青海大学附属医院影像中心,青海 西宁

出　　处：《临床医学进展》2022年第11期10342-10350,共9页Advances in Clinical Medicine

摘　　要：现如今,经动脉化疗栓塞术(transarterial chemoembolization, TACE)已经成为中晚期肝细胞癌(hepatocellular carcinoma, HCC)主要的治疗方式,但是术后的复发率依然较高,TACE术前肿瘤的全面评估以及术后早期的疗效预测显得尤为重要,随着医学影像学技术、人工智能以及分子生物学的不断发展,肝癌患者术后早期疗效评估成为研究热点,本文就肝癌患者在接受TACE术后对于早期疗效预测价值的研究进展进行综述。Nowadays, transarterial chemoembolization (TACE) has become the main treatment for middle- advanced hepatocellular carcinoma (HCC), but the recurrence rate is still high. Comprehensive evaluation of tumor before TACE and early prediction of efficacy after TACE are particularly im-portant. With the continuous development of medical imaging technology, artificial intelligence and molecular biology, the evaluation of early efficacy after hepatocellular carcinoma surgery has be-come a research hotspot. This article reviews the research progress on the predictive value of early efficacy in patients with HCC after TACE.

关 键 词：磁共振成像 钆塞酸二钠 经动脉化疗栓塞术 

分 类 号：R73[医药卫生—肿瘤]